Peter Neubeck is a Medical Doctor, educated at Ludwig-Maximilians-Universität in Munich as well as Harvard Medical School with postgraduate training at Großhadern University Clinic, The Cleveland Clinic and Beth Israel Deaconess Hospital, Boston. After obtaining an MBA from INSEAD Peter started his business career at McKinsey & Company in Zurich and then moved to Novartis where he was leading Global Disease Area Strategy before taking over responsibilities as Global Project Leader for a high profile late stage development project in the space of Cardiovascular Medicine. He entered the Venture Capital industry with TVM Capital in Munich in 2008 where we gained experience both as investment manager and in building, running and successfully exiting several portfolio companies, most notably rare disease company Aspireo which was sold after clinical PoC to Swedish Biotech Cortendo.
Organization Name | Title At Company | Start Date | End Date | |
---|---|---|---|---|
Synendos Therapeutics | Board Member | Nov 12, 2020 | — | Detail |